212 related articles for article (PubMed ID: 22934291)
1. Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
Spyropoulos AC; Douketis JD; Gerotziafas G; Kaatz S; Ortel TL; Schulman S;
J Thromb Haemost; 2012 Apr; 10(4):692-4. PubMed ID: 22934291
[No Abstract] [Full Text] [Related]
2. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Koziński M; Obońska K; Kubica A; Navarese EP; Kubica J
Kardiol Pol; 2012; 70(10):1053-60. PubMed ID: 23080100
[No Abstract] [Full Text] [Related]
3. New oral anticoagulant agents - general features and outcomes in subsets of patients.
Schulman S
Thromb Haemost; 2014 Apr; 111(4):575-82. PubMed ID: 24452881
[TBL] [Abstract][Full Text] [Related]
4. Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.
Blann AD
Br J Biomed Sci; 2014; 71(4):158-67. PubMed ID: 25562993
[TBL] [Abstract][Full Text] [Related]
5. Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
Lane DA; Wood K
Circulation; 2015 Apr; 131(16):e412-5. PubMed ID: 25901074
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Skjøth F; Larsen TB; Rasmussen LH; Lip GY
Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
[TBL] [Abstract][Full Text] [Related]
7. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
[TBL] [Abstract][Full Text] [Related]
8. Direct oral anticoagulants in atrial fibrillation.
Noll G; Noll S; Hürlimann D
Semin Hematol; 2014 Apr; 51(2):139-46. PubMed ID: 24861798
[TBL] [Abstract][Full Text] [Related]
9. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
Sardar P; Chatterjee S; Lavie CJ; Giri JS; Ghosh J; Mukherjee D; Lip GY
Int J Cardiol; 2015 Jan; 179():279-87. PubMed ID: 25464465
[TBL] [Abstract][Full Text] [Related]
10. Bleeding and antidotes in new oral anticoagulants.
Majeed A; Schulman S
Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
[TBL] [Abstract][Full Text] [Related]
11. [Rivaroxaban, dabigatran and apixaban: new anticoagulants in operative urology].
John A; Michel MS
Urologe A; 2014 Jun; 53(6):893-902; quiz 903. PubMed ID: 24845012
[TBL] [Abstract][Full Text] [Related]
12. [New clinical perspectives in the management of oral direct anticoagulant agents].
Marco P; Zamorano JL; Chana F; Llau JV
Med Clin (Barc); 2014 Feb; 142(4):171-8. PubMed ID: 23866969
[No Abstract] [Full Text] [Related]
13. Are new oral anticoagulant dosing recommendations optimal for all patients?
Powell JR
JAMA; 2015 Mar; 313(10):1013-4. PubMed ID: 25756434
[No Abstract] [Full Text] [Related]
14. Perioperative management of patients on new oral anticoagulants.
Lai A; Davidson N; Galloway SW; Thachil J
Br J Surg; 2014 Jun; 101(7):742-9. PubMed ID: 24777590
[TBL] [Abstract][Full Text] [Related]
15. [New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
Oberhofer E
MMW Fortschr Med; 2015 Jan; 157(1):24. PubMed ID: 25743289
[No Abstract] [Full Text] [Related]
16. [Management of direct action oral anticoagulants in the peri-operative period and invasive techniques].
Llau JV; Ferrandis R; Castillo J; de Andrés J; Gomar C; Gómez-Luque A; Hidalgo F; Torres LM;
Rev Esp Anestesiol Reanim; 2012; 59(6):321-30. PubMed ID: 22633209
[TBL] [Abstract][Full Text] [Related]
17. New oral anticoagulants for non-valvular atrial fibrillation--safety issues.
Barry M
Ir Med J; 2013 Mar; 106(3):69. PubMed ID: 23951972
[No Abstract] [Full Text] [Related]
18. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
19. [Bleeding and surgery in the treatment with new oral anticoagulants. The management can be complicated by the lack of specific antidotes].
Dalén M; Hjemdahl P; Holmström M; Ivert T
Lakartidningen; 2014 Jun 11-17; 111(24):1064-8. PubMed ID: 25129916
[No Abstract] [Full Text] [Related]
20. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
Thromb Haemost; 2012 Mar; 107(3):584-9. PubMed ID: 22186961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
